We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+13.66%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$180M
AUM Growth
+$17.3M
Cap. Flow
-$1.67M
Cap. Flow %
-0.93%
Top 10 Hldgs %
91.75%
Holding
43
New
2
Increased
6
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
WKHS icon
Workhorse Group
WKHS
+$801K
2
CLVS
Clovis Oncology, Inc.
CLVS
+$608K
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$456K
4
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$242K
5
AXDX
Accelerate Diagnostics
AXDX
+$183K

Top Sells

Rank Stock Value
1
MASI
Masimo
MASI
+$1.78M
2
CELG
Celgene Corp
CELG
+$1.2M
3
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$316K
4
ARAY icon
Accuray
ARAY
+$287K
5
CHRS icon
Coherus Oncology
CHRS
+$211K

Sector Composition

Rank Sector Weight
1 Healthcare 95.81%
2 Energy 2.89%
3 Consumer Staples 0.45%
4 Consumer Discretionary 0.38%
5 Industrials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$95.4M 53.08%
767,051
-10,000
-1% -$1.2M
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$52.8M 29.39%
218,380
+800
+0.4% +$183K
VRML
3
DELISTED
Vermillion, Inc.
VRML
$5.65M 3.14%
2,752,933
+35,419
+1% +$62.1K
EQT icon
4
EQT Corp
EQT
$31B
$2.58M 1.44%
77,705
– –
BIOL
5
DELISTED
Biolase, Inc.
BIOL
$1.74M 0.97%
103
– –
OVV icon
6
Ovintiv
OVV
$16.2B
$1.55M 0.86%
26,460
– –
MASI
7
DELISTED
Masimo
MASI
$1.4M 0.78%
15,000
-21,600
-59% -$1.78M
TSRO
8
DELISTED
TESARO, Inc.
TSRO
$1.39M 0.77%
9,000
-950
-10% -$155K
CFRX
9
DELISTED
ContraFect Corporation
CFRX
$1.3M 0.73%
906
– –
NBIX icon
10
Neurocrine Biosciences
NBIX
$17.2B
$1.09M 0.61%
25,200
– –
OXFD
11
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$1.04M 0.58%
67,303
– –
MRK icon
12
Merck
MRK
$315B
$953K 0.53%
15,720
– –
WMGI
13
DELISTED
Wright Medical Group Inc
WMGI
$934K 0.52%
30,000
– –
QDEL icon
14
QuidelOrtho
QDEL
$1.19B
$882K 0.49%
38,975
– –
VCYT icon
15
Veracyte
VCYT
$4.72B
$870K 0.48%
94,767
+15,000
+19% +$123K
YTEN
16
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$807K 0.45%
236
– –
NXTM
17
DELISTED
NxStage Medical Inc.
NXTM
$757K 0.42%
28,200
– –
VNDA icon
18
Vanda Pharmaceuticals
VNDA
$327M
$756K 0.42%
54,000
+32,000
+145% +$456K
WKHS icon
19
Workhorse Group
WKHS
$28.6M
$684K 0.38%
87
+77
+770% +$801K
CORT icon
20
Corcept Therapeutics
CORT
$9.72B
$658K 0.37%
60,000
-20,000
-25% -$176K
CLVS
21
DELISTED
Clovis Oncology, Inc.
CLVS
$637K 0.35%
+10,000
New +$608K
PXD
22
DELISTED
Pioneer Natural Resource Co.
PXD
$559K 0.31%
3,000
– –
SIEN
23
DELISTED
Sientra, Inc.
SIEN
$533K 0.3%
6,330
– –
CTRA
24
DELISTED
Coterra Energy
CTRA
$502K 0.28%
21,000
– –
QTNT
25
DELISTED
Quotient Limited Ordinary Shares
QTNT
$407K 0.23%
1,455
– –
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Birchview Capital held 43 positions worth $180M, up 11% from $163M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Birchview Capital's Q1 2017 filing shows 2 new, 6 increased, 6 reduced and 2 closed positions. Its largest new stake was Clovis Oncology, Inc.: 10,000 shares worth $637K. The largest sale was Masimo, an estimated $1.78M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q1 2017 buy was Clovis Oncology, Inc.: 10,000 shares worth $637K.
  • Birchview Capital added most to Workhorse Group in Q1 2017, an estimated $801K increase.
  • Birchview Capital's biggest Q1 2017 reduction was Masimo, cutting an estimated $1.78M.
  • Birchview Capital fully exited Coherus Oncology in Q1 2017, selling an estimated $211K.
  • Birchview Capital's ten largest holdings make up 92% of its $180M portfolio in Q1 2017.
  • Birchview Capital opened 2 new positions and closed 2 in Q1 2017.
  • Birchview Capital's portfolio value rose 11% quarter-over-quarter to $180M.

Based on Birchview Capital's 13F filing for Q1 2017, filed 4 May 2017.